<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36558963</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Update on COVID-19 Therapy in Pediatric Age.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1512</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph15121512</ELocationID><Abstract><AbstractText>With the extension of the COVID-19 pandemic, the large use of COVID-19 vaccines among adults and the emergence of SARS-CoV-2 variants means that the epidemiology of COVID-19 in pediatrics, particularly among younger children, has substantially changed. The prevalence of pediatric COVID-19 significantly increased, several severe cases among children were reported, and long-COVID in pediatric age was frequently observed. The main aim of this paper is to discuss which types of treatment are presently available for pediatric patients with COVID-19, which of them are authorized for the first years of life, and which are the most important limitations of COVID-19 therapy in pediatric age. Four different antivirals, remdesivir (RVD), the combination nirmatrelvir plus ritonavir (Paxlovid), molnupiravir (MPV), and the monoclonal antibody bebtelovimab (BEB), are presently approved or authorized for emergency use for COVID-19 treatment by most of the national health authorities, although with limitations according to the clinical relevance of disease and patient's characteristics. Analyses in the literature show that MPV cannot be used in pediatric age for the risk of adverse events regarding bone growth. The other antivirals can be used, at least in older children, and RDV can be used in all children except in neonates. However, careful research on pharmacokinetic and clinical data specifically collected in neonates and children are urgently needed for the appropriate management of pediatric COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Autore</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5895-8313</Identifier><AffiliationInfo><Affiliation>Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argentiero</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6597-5461</Identifier><AffiliationInfo><Affiliation>Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramundo</LastName><ForeName>Greta</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrone</LastName><ForeName>Serafina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5478-5657</Identifier><AffiliationInfo><Affiliation>Neonatoloy Unit, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Principi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3468-5568</Identifier><AffiliationInfo><Affiliation>Universit&#xe0; degli Studi di Milano, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">antiviral therapy</Keyword><Keyword MajorTopicYN="N">bebtelovimab</Keyword><Keyword MajorTopicYN="N">molnupiravir</Keyword><Keyword MajorTopicYN="N">nirmatrelvir/ritonavir</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>1</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36558963</ArticleId><ArticleId IdType="pmc">PMC9783267</ArticleId><ArticleId IdType="doi">10.3390/ph15121512</ArticleId><ArticleId IdType="pii">ph15121512</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cui X., Zhao Z., Zhang T., Guo W., Guo W., Zheng J. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19) J. Med. Virol. 2021;93:1057&#x2013;1069. doi: 10.1002/jmv.26398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26398</ArticleId><ArticleId IdType="pmc">PMC7436402</ArticleId><ArticleId IdType="pubmed">32761898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsankov B.K., Allaire J.M., Irvine M.A., Lopez A.A., Sauve L.J., Vallance B.A., Jacobson K. Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis. Int. J. Infect. Dis. 2021;103:246&#x2013;256. doi: 10.1016/j.ijid.2020.11.163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.11.163</ArticleId><ArticleId IdType="pmc">PMC7679116</ArticleId><ArticleId IdType="pubmed">33227520</ArticleId></ArticleIdList></Reference><Reference><Citation>Garazzino S., Montagnani C., Don&#xe0; D., Meini A., Felici E., Vergine G., Bernardi S., Giacchero R., Lo Vecchio A., Marchisio P., et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020;25:2000600. doi: 10.2807/1560-7917.ES.2020.25.18.2000600.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.18.2000600</ArticleId><ArticleId IdType="pmc">PMC7219028</ArticleId><ArticleId IdType="pubmed">32400362</ArticleId></ArticleIdList></Reference><Reference><Citation>American Academy of Pediatrics and the Children&#x2019;s Hospital Association  Children and COVID-19: State Data Report.  [(accessed on 6 October 2022)].  Available online:  https://downloads.aap.org/AAP/PDF/AAP%20and%20CHA%20-%20Children%20and%20COVID-19%20State%20Data%20Report%209.29.22%20FINAL.pdf?_ga=2.170767266.309218142.1664893746-995825483.1664893746.</Citation></Reference><Reference><Citation>Food and Drug Administration  FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age.  [(accessed on 10 October 2022)]; Available online:  https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age.</Citation></Reference><Reference><Citation>Food and Drug Administration Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age.  [(accessed on 10 October 2022)]; Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children.</Citation></Reference><Reference><Citation>Zimmermann P., Uka A., Buettcher M., Foug&#xe8;re Y., Plebani M., Relly C., Schmid H., Ritz N., Swiss Paediatric Surveillance Unit (SPSU) Neonates with SARS-CoV-2 infection: Spectrum of disease from a prospective nationwide observational cohort study. Swiss. Med. Wkly. 2022;152:w30185.</Citation><ArticleIdList><ArticleId IdType="pubmed">35748304</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S., Giordano R., Paini G., Puntoni M., Principi N., Caminiti C. Can we get out of the COVID pandemic without adequate vaccination coverage in the pediatric population? Ital. J. Pediatr. 2022;48:150. doi: 10.1186/s13052-022-01339-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-022-01339-x</ArticleId><ArticleId IdType="pmc">PMC9389475</ArticleId><ArticleId IdType="pubmed">35986340</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks K.J., Whitaker M., Agathis N.T., Anglin O., Milucky J., Patel K., Pharm H., Kirley P.D., Kawasaki B., Milucky J., et al. Hospitalization of Infants and Children Aged 0&#x2013;4 Years with Laboratory-Confirmed COVID-19&#x2014;COVID-NET, 14 States, March 2020&#x2013;February 2022. MMWR Morb. Mortal. Wkly Rep. 2022;71:429&#x2013;436. doi: 10.15585/mmwr.mm7111e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7111e2</ArticleId><ArticleId IdType="pmc">PMC8942304</ArticleId><ArticleId IdType="pubmed">35298458</ArticleId></ArticleIdList></Reference><Reference><Citation>Molloy E.J., Nakra N., Gale C., Dimitriades V.R., Lakshminrusimha S. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: Optimizing definition and management. Pediatr. Res. 2022:1&#x2013;10. doi: 10.1038/s41390-022-02263-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-022-02263-w</ArticleId><ArticleId IdType="pmc">PMC9436161</ArticleId><ArticleId IdType="pubmed">36050390</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S., Principi N. Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2. Paediatr. Drugs. 2021;23:119&#x2013;129. doi: 10.1007/s40272-020-00435-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40272-020-00435-x</ArticleId><ArticleId IdType="pmc">PMC7819738</ArticleId><ArticleId IdType="pubmed">33479801</ArticleId></ArticleIdList></Reference><Reference><Citation>More K., Aiyer S., Goti A., Parikh M., Sheikh S., Patel G., Kallem V., Soni R., Kumar P. Multisystem inflammatory syndrome in neonates (MIS-N) associated with SARS-CoV2 infection: A case series. Eur. J. Pediatr. 2022;181:1883&#x2013;1898. doi: 10.1007/s00431-022-04377-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-022-04377-z</ArticleId><ArticleId IdType="pmc">PMC8759431</ArticleId><ArticleId IdType="pubmed">35031848</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar R., Gavade V., Patil N., Mali V., Girwalkar A., Tarkasband V., Loya S., Chavan A., Nanivadekar N., Shinde R., et al. Neonatal Multisystem Inflammatory Syndrome (MIS-N) Associated with Prenatal Maternal SARS-CoV-2: A Case Series. Children. 2021;8:572. doi: 10.3390/children8070572.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children8070572</ArticleId><ArticleId IdType="pmc">PMC8305422</ArticleId><ArticleId IdType="pubmed">34356552</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson T., Shafran R., Ladhani S.N. Long COVID in children and adolescents. Curr. Opin. Infect. Dis. 2022;35:461&#x2013;467. doi: 10.1097/QCO.0000000000000854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000854</ArticleId><ArticleId IdType="pmc">PMC9553244</ArticleId><ArticleId IdType="pubmed">36098262</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S., Principi N., Azzari C., Cardinale F., Di Mauro G., Galli L., Gattinara G.C., Fainardi V., Guarino A., Lancella L., et al. Italian intersociety consensus on management of long covid in children. Ital. J. Pediatr. 2022;48:42. doi: 10.1186/s13052-022-01233-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-022-01233-6</ArticleId><ArticleId IdType="pmc">PMC8905554</ArticleId><ArticleId IdType="pubmed">35264214</ArticleId></ArticleIdList></Reference><Reference><Citation>Fainardi V., Meoli A., Chiopris G., Motta M., Skenderaj K., Grandinetti R., Bergomi A., Antodaro F., Zona S., Esposito S. Long COVID in Children and Adolescents. Life. 2022;12:285. doi: 10.3390/life12020285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12020285</ArticleId><ArticleId IdType="pmc">PMC8876679</ArticleId><ArticleId IdType="pubmed">35207572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Ayuzo Del Valle N.C., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. Long-COVID in children and adolescents: A systematic review and meta-analyses. Sci. Rep. 2022;12:9950. doi: 10.1038/s41598-022-13495-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13495-5</ArticleId><ArticleId IdType="pmc">PMC9226045</ArticleId><ArticleId IdType="pubmed">35739136</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatti E., Piotto M., Lelii M., Pensabene M., Madini B., Cerrato L., Hassan V., Aliberti S., Bosis S., Marchisio S., et al. Therapeutic Strategies for COVID-19 Lung Disease in Children. Front. Pediatr. 2022;10:829521. doi: 10.3389/fped.2022.829521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.829521</ArticleId><ArticleId IdType="pmc">PMC8936419</ArticleId><ArticleId IdType="pubmed">35321012</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency  Comirnaty.  [(accessed on 1 November 2022)].  Available online:  https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty#authorisation-details-section.</Citation></Reference><Reference><Citation>Principi N., Esposito S. Is the Immunization of Pregnant Women against COVID-19 Justified? Vaccines. 2021;9:970. doi: 10.3390/vaccines9090970.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9090970</ArticleId><ArticleId IdType="pmc">PMC8473171</ArticleId><ArticleId IdType="pubmed">34579207</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan A.K., Kaur R., Nosek M., Swathi P.A., Gu N.Y. COVID-19 vaccine acceptance and coverage among pregnant persons in the United States. Prev. Med. Rep. 2022;29:101977. doi: 10.1016/j.pmedr.2022.101977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2022.101977</ArticleId><ArticleId IdType="pmc">PMC9450469</ArticleId><ArticleId IdType="pubmed">36090471</ArticleId></ArticleIdList></Reference><Reference><Citation>American Academy of Pediatrics  Children and COVID-19 Vaccination Trends.  [(accessed on 10 October 2022)].  Available online:  https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-vaccination-trends/</Citation></Reference><Reference><Citation>Kokic G., Hillen H.S., Tegunov D., Dienemann C., Seitz F., Schmitzova J., Farnung L., Siewert A., H&#xf6;bartner C., Cramer P. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 2021;12:279. doi: 10.1038/s41467-020-20542-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20542-0</ArticleId><ArticleId IdType="pmc">PMC7804290</ArticleId><ArticleId IdType="pubmed">33436624</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration  Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children.  [(accessed on 10 October 2022)]; Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children.</Citation></Reference><Reference><Citation>Chan-Tack K., Sampson M., Earp J., Arya V., Yao L., Alexander J., Hausman E., Belew Y., Birnkrant E., Struble K., et al. Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development Program. J. Clin. Pharmacol. 2022 doi: 10.1002/jcph.2158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.2158</ArticleId><ArticleId IdType="pmc">PMC9538509</ArticleId><ArticleId IdType="pubmed">36149807</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman D.L., Aldrich M.L., Hagmann S.H.F., Bamford A., Camacho-Gonzalez A., Lapadula G., Lee P., Bonfanti P., Carter C.C., Zhao Y., et al. Compassionate Use of Remdesivir in Children with Severe COVID-19. Pediatrics. 2021;147:e2020047803. doi: 10.1542/peds.2020-047803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2020-047803</ArticleId><ArticleId IdType="pubmed">33883243</ArticleId></ArticleIdList></Reference><Reference><Citation>La Tessa A., Motisi M.A., Marseglia G.L., Cardinale F., Licari A., Manti S., Tosca M., Del Giudice M.M., de Filippo M., Galli L., et al. Use of remdesivir in children with COVID-19 infection: A quick narrative review. Acta Biomed. 2021;92:e2021524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9431884</ArticleId><ArticleId IdType="pubmed">34842595</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the treatment of COVID-19&#x2014;Final report. N. Engl. J. Med. 2020;383:1813&#x2013;1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman J.D., Lye D.C.B., Hui D.S., Marks K.M., Bruno R., Montejano R., Spinner C.D., Galli M., Ahn M.-Y., Nahass R.-G., et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N. Engl. J. Med. 2020;383:1827&#x2013;1837. doi: 10.1056/NEJMoa2015301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015301</ArticleId><ArticleId IdType="pmc">PMC7377062</ArticleId><ArticleId IdType="pubmed">32459919</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinner C.D., Gottlieb R.L., Criner G.J., Arribas L&#xf3;pez J.R., Cattelan A.M., Ogbuagu O., Malhotra P., Mullane K.M., Castagna A., Chai L.Y.A., et al. Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA. 2020;24:1048&#x2013;1057. doi: 10.1001/jama.2020.16349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16349</ArticleId><ArticleId IdType="pmc">PMC7442954</ArticleId><ArticleId IdType="pubmed">32821939</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang W., Dai W., Yao C., Xu L., Tao X., Su H., Li J., Xie X., Xu Y., Hu M., et al. In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. Antivir. Res. 2022 doi: 10.1016/j.antiviral.2022.105450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105450</ArticleId><ArticleId IdType="pmc">PMC9617675</ArticleId><ArticleId IdType="pubmed">36354082</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb R.L., Vaca C.E., Paredes R., Mera J., Webb B.J., Perez G., Oguchi G., Pyan P., Nielsen B.U., Brown M., et al. Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients. N. Engl. J. Med. 2022;386:305&#x2013;315. doi: 10.1056/NEJMoa2116846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilead  Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury&#xae; (Remdesivir) in Pediatric Patients with COVID-19 Presented at CROI. 2022.  [(accessed on 10 October 2022)].  Available online:  https://www.gilead.com/news-and-press/press-room/press-releases/2022/2/phase-23-interim-data-evaluating-the-safety-tolerability-and-clinical-outcomes-of-veklury-remdesivir-in-pediatric-patients-with-covid19-present.</Citation></Reference><Reference><Citation>Gomez R.A., Sequeira Lopez M.L., Fernandez L., Cher&#xf1;avvsky D.R., Norwood V.F. The maturing kidney: Development and susceptibility. Ren. Fail. 1999;21:283&#x2013;291. doi: 10.3109/08860229909085090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08860229909085090</ArticleId><ArticleId IdType="pubmed">10416205</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamsick M.L., Gandhi R.G., Bidell M.R., Elshaboury R.H., Bhattacharyya R.P., Kim A.Y., Nigwekar S., Rhee E.P., Sise M.E. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. J. Am. Soc. Nephrol. 2020;31:1384&#x2013;1386. doi: 10.1681/ASN.2020050589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020050589</ArticleId><ArticleId IdType="pmc">PMC7351006</ArticleId><ArticleId IdType="pubmed">32513665</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA  Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid.  [(accessed on 3 November 2022)]; Available online:  https://www.fda.gov/media/155050/download.</Citation></Reference><Reference><Citation>Lewnard J.A., Malden D., Hong V., Puzniak L., Kim J.S., Shaw S.F., Takhar H., Jodar L., McLaughlin J.M., Tartof S.Y. Effectiveness of nirmatrelvir-ritonavir against hospital admission: A matched cohort study in a large US healthcare system. medRxiv. 2022 doi: 10.1101/2022.10.02.22280623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.02.22280623</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simon-Campos A., et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N. Engl. J. Med. 2022;386:1397&#x2013;1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Q., Ma P., Wang M., Cheng Y., Zhou M., Ye L., Feng Z., Zhang C. Efficacy and safety of Paxlovid for COVID-19: A meta-analysis. J. Infect. 2022;S163-4453:00557-6. doi: 10.1016/j.jinf.2022.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.09.027</ArticleId><ArticleId IdType="pmc">PMC9523907</ArticleId><ArticleId IdType="pubmed">36191676</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai E.Y., Lee K.A., Nathanson A.B., Leonelli A.T., Petros B.A., Brock-Fisher T., Dobbins S.T., Maclnns B.L., Capone A., Littlehale N., et al. Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir. medRxiv. 2022 doi: 10.1101/2022.08.04.22278378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.04.22278378</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Berger N.A., Davis P.B., Kaelber D.C., Volkow N.D., Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January&#x2013;June 2022. medRxiv. 2022 doi: 10.1101/2022.06.21.22276724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.21.22276724</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Gao M., You H., Zhang P., Pan Y., Li N., Qin L., Wang H., Li D., Li L., et al. Association of nirmatrelvir/ritonavir treatment on upper respiratory SARS-CoV-2 RT-PCR negative conversion rates among high-risk patients with COVID-19. Clin. Infect. Dis. 2022:ciac600. doi: 10.1093/cid/ciac600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac600</ArticleId><ArticleId IdType="pmc">PMC9384507</ArticleId><ArticleId IdType="pubmed">35870128</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan G., Zhou J., Zhu H., Chen Y., Lu Y., Zhang T., Hui Y., Wang L., Xu H., Wang Z., et al. The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6&#x2013;14 years: A cohort study. Ann. Transl. Med. 2022;10:619. doi: 10.21037/atm-22-2791.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-22-2791</ArticleId><ArticleId IdType="pmc">PMC9263777</ArticleId><ArticleId IdType="pubmed">35813342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearns G.L., Abdel-Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., Kauffman R.E. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 2003;349:1157&#x2013;1167. doi: 10.1056/NEJMra035092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra035092</ArticleId><ArticleId IdType="pubmed">13679531</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkin H.D. Paxlovid Drug Interaction Screening Checklist Updated. JAMA. 2022;328:1290. doi: 10.1001/jama.2022.15442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.15442</ArticleId><ArticleId IdType="pubmed">36194234</ArticleId></ArticleIdList></Reference><Reference><Citation>Westendorf K., &#x17d;entelis S., Wang L., Foster D., Vaillancourt P., Wiggin M., Lovett E., van der Lee R., Hendle J., Pustilnik A., et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022;39:110812. doi: 10.1016/j.celrep.2022.110812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110812</ArticleId><ArticleId IdType="pmc">PMC9035363</ArticleId><ArticleId IdType="pubmed">35568025</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration  Fact sheet for healthcare providers: Emergency use authorization for Bebtelovimab.  [(accessed on 10 October 2022)]; Available online:  https://www.fda.gov/media/156152/download.</Citation></Reference><Reference><Citation>Chigutsa E., Jordie E., Riggs M., Nirula A., Elmokadem A., Knab T., Chien J.Y. A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal Antibodies to Advance Bamlanivimab into a First-in-Human Clinical Trial. Clin. Pharmacol. Ther. 2022;111:595&#x2013;604. doi: 10.1002/cpt.2459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2459</ArticleId><ArticleId IdType="pmc">PMC8653169</ArticleId><ArticleId IdType="pubmed">34687040</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Health  Anti-SARS-CoV-2 Monoclonal Antibodies.  [(accessed on 10 October 2020)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/</Citation></Reference><Reference><Citation>Dougan M., Azizad M., Chen P., Feldman B., Frieman M., Igbinadolor A., Kumar P., Morris J., Potts J., Baracco L. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv. 2022 doi: 10.1101/2022.03.10.22272100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.10.22272100</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Schinazi R.F., G&#xf6;tte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 2021;297:100770. doi: 10.1016/j.jbc.2021.100770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100770</ArticleId><ArticleId IdType="pmc">PMC8110631</ArticleId><ArticleId IdType="pubmed">33989635</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration  Emergency Use Authorization.  [(accessed on 10 October 2022)]; Available online:  https://www.fda.gov/media/155053/download.</Citation></Reference><Reference><Citation>European Medicines Agency  Assessment Report. Use of Molnupiravir for the Treatment of COVID-19.  [(accessed on 10 October 2022)].  Available online:  https://www.ema.europa.eu/en/documents/referral/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf.</Citation></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Reyes V.D., Mart&#xed;n-Quir&#xf3;s A., Caraco Y., Williams-Diaz A., Brown M.L., et al. MOVe-OUT Study Group. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N. Engl. J. Med. 2022;386:509&#x2013;520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>